FDA Approves RINVOQ — AbbVie Inc.

Attribution of this breakthrough can be reserved for the **AbbVie** approval of the oral rheumatoid arthritis therapy RINVOQ (upadacitinib). The nod reflects intense **market** competition against blockbuster drugs like Johnson & Johnson’s Tremfya and Amgen’s Otezla, though analysts expect the asset to maintain significant commercial momentum given its differentiated efficacy profile.